Neoadjuvant therapy in non-small cell lung cancer

被引：4
|
作者：
Grant, Christopher [1 ]
Hagopian, Garo [1 ]
Nagasaka, Misako [1 ,2 ,3 ,4 ]
机构：
[1] Univ Calif Irvine, Sch Med, Dept Med, Orange, CA USA
[2] Univ Calif Irvine, Sch Med, Dept Med, Div Hematol & Oncol, Orange, CA USA
[3] St Marianna Univ, Sch Med, Dept Internal Med, Div Neurol, Kawasaki 2168511, Japan
[4] Univ Calif Irvine, UC Irvine Hlth, Med Ctr, Dept Med,Div Hematol & Oncol, 200 S Manchester Ave, Room 423, Orange, CA 92868 USA
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2023年 / 190卷
关键词：
Perioperative chemotherapy; Perioperative immunotherapy; Neoadjuvant targeted therapy; CheckMate; 816; AEGEAN; PHASE-III; INDUCTION CHEMOTHERAPY; PLUS CHEMOTHERAPY; OPEN-LABEL; SURGERY; TRIAL; PEMBROLIZUMAB; OSIMERTINIB;
D O I：
10.1016/j.critrevonc.2023.104080
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Non-small cell lung cancer (NSCLC) stages I-III were previously predominantly treated with surgery and chemotherapy. With the advent of Checkmate-816, neoadjuvant nivolumab and chemotherapy was FDA approved for the treatment of resectable NSCLC. There are several ongoing trials evaluating other neoadjuvant combinations of chemotherapy and immunotherapy as well as targeted therapies towards driver mutations. Here, we review previous clinical trials and discuss current ongoing trials' potential benefits and challenges.
引用
收藏
页数：8
相关论文
共 50 条
  • [31] Neoadjuvant Intratumoral Immuno-Gene Therapy for Non-Small Cell Lung Cancer
    Predina, Jarrod D.
    Keating, Jane
    Venegas, Ollin
    Nims, Sarah
    Singhal, Sunil
    [J]. DISCOVERY MEDICINE, 2016, 21 (116) : 275 - 281
  • [32] Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series
    Hu, Yan
    Ren, Siying
    Yang, Lulu
    Tong, Zhongyi
    Wang, Ruoyao
    Han, Wei
    Zeng, Chao
    Li, Jina
    Xiao, Peng
    Wang, Li
    Yu, Fenglei
    Liu, Wenliang
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [33] Neoadjuvant therapy for locally advanced non-small cell lung cancer: TKIs or immunotherapy?
    Zhang, Zhenyang
    Lin, Jiangbo
    Kang, Mingqiang
    [J]. JOURNAL OF THORACIC DISEASE, 2020, 12 (03) : 1151 - 1153
  • [34] Uptake and disparities of neoadjuvant therapy for stage III non-small cell lung cancer
    Becker, Daniel Jacob
    Levy, Benjamin Philip
    Grossbard, Michael L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] Comprehensive study of neoadjuvant targeted therapy for resectable non-small cell lung cancer
    Bao, Yi
    Gu, Chang
    Xie, Huikang
    Zhao, Shengnan
    Xie, Dong
    Chen, Chang
    Jiang, Gening
    Dai, Chenyang
    Zhu, Yuming
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (06)
  • [36] Perioperative therapy of non-small cell lung cancer: A review of adjuvant and neoadjuvant approaches
    Friedland, DM
    Comis, RL
    [J]. SEMINARS IN ONCOLOGY, 1995, 22 (06) : 571 - 581
  • [37] NEOSTAR trial and the current status of neoadjuvant therapy in non-small cell lung cancer
    Sepesi, Boris
    Mehran, Reza
    Spicer, Jonathan
    Cascone, Tina
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2024, 167 (06): : 1936 - 1942
  • [38] NEOADJUVANT THERAPY OF STAGE-III NON-SMALL CELL LUNG-CANCER
    EINHORN, LH
    [J]. ANNALS OF THORACIC SURGERY, 1988, 46 (03): : 362 - 365
  • [39] Thoracoscopic staging of IIIB non-small cell lung cancer before neoadjuvant therapy
    DeGiacomo, T
    Rendina, EA
    Venuta, F
    DellaRocca, G
    Ricci, C
    [J]. ANNALS OF THORACIC SURGERY, 1997, 64 (05): : 1409 - 1411
  • [40] Docetaxel in neoadjuvant therapy of early-stage non-small cell lung cancer
    Betticher, DC
    [J]. ONKOLOGIE, 2003, 26 : 33 - 36
12345